Patient Characteristics

Patients Characteristics¹

Patients receiving Voraxaze^® with:

• No pre-existing grade 4 toxicity before Voraxaze^® administration
• The appropriate increase in leucovorin rescue within 3 days after the start of HDMTX infusion

Administration of Voraxaze^®

• ≤ 96 hours after HDMTX exposure, n = 64
• 96 hours after HDMTX exposure, n = 11

Inclusion Criteria¹

Patients with MTX-included nephrotoxicity and delayed MTX excretion were eligible for treatment with Voraxaze^®, if either of the following two conditions were met:

• Plasma MTX concentration was ≥10 μmol/L ≥42 hours after the start of HDMTX infusion
• sCr was ≥1.5 times the upper limit of normal or CrCl was ≤ 60mL/min/m² and the plasma MTX concentration was ≥2 standard deviations above the mean ≥12 hours after MTX administration

Abbreviations: CrCl, creatinine clearance; HDMTX, high dose methotrexate; MTX, methotrexate; sCr, serum creatinine.